{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T16:55:11Z","timestamp":1768668911079,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Epizyme, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s12325-022-02054-z","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T13:36:27Z","timestamp":1644845787000},"page":"1678-1696","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib"],"prefix":"10.1007","volume":"39","author":[{"given":"David","family":"Proudman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dave","family":"Nellesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepshekhar","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deyaa","family":"Adib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Mamlouk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,14]]},"reference":[{"key":"2054_CR1","unstructured":"Surveillance Epidemiology and End Results Program. SEER Cancer Stat Facts: NHL - Follicular Lymphoma. 2020. https:\/\/seer.cancer.gov\/statfacts\/html\/follicular.html. Accessed Mar 27 2020."},{"key":"2054_CR2","unstructured":"Alperovich A, Batlevi C, Smith K, et al. Benchmark of progression-free survival for multiple lines of therapy in follicular lymphoma treated in the rituximab era [abstract]. Presented at: 58th American Society of Hematology Annual Meeting and Exposition; December 3\u20136, 2016; San Diego, CA."},{"key":"2054_CR3","unstructured":"Zydelig [package insert]. Foster City, CA: Gilead Sciences Inc., 2018."},{"key":"2054_CR4","unstructured":"Copiktra [package insert]. Needham, MA: Verastem, Inc., 2019."},{"key":"2054_CR5","unstructured":"Aliqopa [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, 2020."},{"key":"2054_CR6","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1200\/JCO.20.03433","volume":"39","author":"NH Fowler","year":"2021","unstructured":"Fowler NH, Samaniego F, Jurczak W, et al. Umbralisib, a dual PI3K\u03b4\/CK1\u03b5 inhibitor in patients with relapsed or refractory indolent lymphoma. J Clin Oncol. 2021;39:1609\u201318.","journal-title":"J Clin Oncol"},{"key":"2054_CR7","unstructured":"Bodor C, Batlevi C, Nagy N, et al. EZH2 gain-of-function mutations are not associated with more favorable prognosis in relapsed\/refractory follicular lymphoma: a preliminary analysis on 908 patients. 24th European Hematology Association Congress Amsterdam, Netherlands, 2019."},{"key":"2054_CR8","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood-2013-04-496893","volume":"122","author":"C Bodor","year":"2013","unstructured":"Bodor C, Grossmann V, Popov N, et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood. 2013;122:3165\u20138.","journal-title":"Blood"},{"key":"2054_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.32","volume":"7","author":"S Huet","year":"2017","unstructured":"Huet S, Xerri L, Tesson B, et al. EZH2 alterations in follicular lymphoma: biological and clinical correlations. Blood Cancer J. 2017;7: e555.","journal-title":"Blood Cancer J"},{"key":"2054_CR10","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1158\/1078-0432.CCR-13-1597","volume":"20","author":"S Guo","year":"2014","unstructured":"Guo S, Chan JK, Iqbal J, et al. EZH2 mutations in follicular lymphoma from different ethnic groups and associated gene expression alterations. Clin Cancer Res. 2014;20:3078\u201386.","journal-title":"Clin Cancer Res"},{"key":"2054_CR11","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/leu.2010.311","volume":"25","author":"C Bodor","year":"2011","unstructured":"Bodor C, O\u2019Riain C, Wrench D, et al. EZH2 Y641 mutations in follicular lymphoma. Leukemia. 2011;25:726\u20139.","journal-title":"Leukemia"},{"key":"2054_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.mrfmmm.2008.07.010","volume":"647","author":"JA Simon","year":"2008","unstructured":"Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res. 2008;647:21\u20139.","journal-title":"Mutat Res"},{"key":"2054_CR13","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ccr.2013.04.011","volume":"23","author":"W Beguelin","year":"2013","unstructured":"Beguelin W, Popovic R, Teater M, et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell. 2013;23:677\u201392.","journal-title":"Cancer Cell"},{"key":"2054_CR14","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nature09784","volume":"469","author":"R Margueron","year":"2011","unstructured":"Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature. 2011;469:343\u20139.","journal-title":"Nature"},{"key":"2054_CR15","unstructured":"Epizyme Inc. TAZVERIK\u2122 [Prescribing Information]. Epizyme, 2020."},{"key":"2054_CR16","unstructured":"National Comprehensive Cancer Network (NCCN). B-Cell Lymphomas (Version 4.2020). 2020."},{"key":"2054_CR17","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","volume":"370","author":"AK Gopal","year":"2014","unstructured":"Gopal AK, Kahl BS, Vos S, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370:1008\u201318.","journal-title":"N Engl J Med"},{"key":"2054_CR18","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1200\/JCO.18.00915","volume":"37","author":"IW Flinn","year":"2019","unstructured":"Flinn IW, Miller CB, Ardeshna KM, et al. DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. J Clin Oncol. 2019;37:912\u201322.","journal-title":"J Clin Oncol"},{"key":"2054_CR19","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/ajh.25711","volume":"95","author":"M Dreyling","year":"2019","unstructured":"Dreyling M, Santoro A, Mollica L, et al. Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study. Amer J Hematol. 2019;95:362\u201371.","journal-title":"Amer J Hematol"},{"key":"2054_CR20","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","volume":"35","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Santoro A, Mollica L, et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J Clinl Oncol. 2017;35:3898\u2013905.","journal-title":"J Clinl Oncol"},{"key":"2054_CR21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1182\/blood-2019-128096","volume":"134","author":"F Morschhauser","year":"2019","unstructured":"Morschhauser F, Tilly H, Chaidos A, et al. Phase\u00a02 multicenter study of tazemetostat, an EZH2 inhibitor, in patients with relapsed or refractory follicular lymphoma. Blood. 2019;134:123.","journal-title":"Blood"},{"key":"2054_CR22","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","volume":"21","author":"F Morschhauser","year":"2020","unstructured":"Morschhauser F, Tilly H, Chaidos A, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase\u00a02 trial. Lancet Oncol. 2020;21:1433\u201342.","journal-title":"Lancet Oncol"},{"key":"2054_CR23","unstructured":"Food and Drug Administration. Application Number: 211155Orig1s000\/211155Orig2s000. Silver Spring: Center for Drug Evaluation and Research; 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/211155Orig1Orig2s000AdminCorres.pdf. Accessed 5 Apr 2020."},{"key":"2054_CR24","unstructured":"Food and Drug Administration. Application Number: 211155Orig1s000\/211155Orig2s000, Product Quality Reviews. Silver Spring: Center for Drug Evaluation and Research, Food and Drug Administration, 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/211155Orig1Orig2s000MultidisciplineR.pdf. Accessed July 6, 2021."},{"key":"2054_CR25","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1182\/blood-2016-12-757740","volume":"129","author":"AK Gopal","year":"2017","unstructured":"Gopal AK, Kahl BS, Flowers CR, et al. Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. Blood. 2017;129:3037\u20139.","journal-title":"Blood"},{"key":"2054_CR26","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/hon.6_2630","volume":"37","author":"J Okosun","year":"2019","unstructured":"Okosun J, B\u00f6d\u00f6r C, Batlevi C, et al. EZH2 gain-of-function mutations are not associated with more favorable prognosis in relapsed\/refractory follicular lymphoma (FL): a preliminary analysis on 590 patients. Hematol Oncol. 2019;37:192\u20133.","journal-title":"Hematol Oncol"},{"key":"2054_CR27","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579\u201386.","journal-title":"J Clin Oncol"},{"key":"2054_CR28","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368.","journal-title":"J Clin Oncol"},{"key":"2054_CR29","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","volume":"15","author":"JE Signorovitch","year":"2012","unstructured":"Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15:940\u20137.","journal-title":"Value Health"},{"key":"2054_CR30","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/ajh.24401","volume":"91","author":"C Nabhan","year":"2016","unstructured":"Nabhan C, Zhou X, Day BM, et al. Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States. Am J Hematol. 2016;91:770\u20135.","journal-title":"Am J Hematol"},{"key":"2054_CR31","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national lymphocare study. J Clin Oncol. 2015;33:2516\u201322.","journal-title":"J Clin Oncol"},{"key":"2054_CR32","doi-asserted-by":"publisher","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","volume":"28","author":"JE Signorovitch","year":"2010","unstructured":"Signorovitch JE, Wu EQ, Yu AP, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics. 2010;28:935\u201345.","journal-title":"Pharmacoeconomics"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02054-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02054-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02054-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T11:40:19Z","timestamp":1649331619000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02054-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,14]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["2054"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02054-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,14]]},"assertion":[{"value":"8 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}